Gilead Sciences
Bookmark
ShareGilead Sciences is a company. It is in Foster City, the United States and it has a male CEO called Daniel P. O'Day. It was founded in 1987 and is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Key facts
- city: Foster City
- state: CA
- country: United States
- employees: 14,400 people
- revenues: 27.5B $
- sector: Health Care
- industry: Pharmaceuticals
- foundation year: 1987
- CEO: Daniel P. O'Day
- CEO gender: male
- CEO approval: 89 %
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about Gilead Sciences:
Stocks from Gilead Sciences:
Gilead Sciences is one of the companies in Daniel P. O'Day, companies in the United States, companies in Pharmaceuticals, companies in Health Care and 3,584,319 companies in our database.
Talking Points
- Gilead Sciences, Inc.
- Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
- The impossible is not impossible. It’s simply what hasn’t been achieved yet. Twitter guidelines: https://t.co/vWkdtfUf7N
- Our ~12,000 employees band together through science, grit, compassion and courage to prove the impossible wrong. At Gilead, the tangible results of your contributions are evident. Where every individual matters. Where all employees can enhance their skills through ongoing development.
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
